Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma [Phase 1]
Phase 1 study evaluating a combination of alvocidib, fludarabine phosphate, and rituximab in various B-cell lymphoproliferative disorders, w…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]
This clinical trial update notes the completion of Phase 1 and Phase 2 studies of oblimersen (Genasense) in patients with relapsed or refrac…
-
CLINICAL_TRIALS trial_result · 2013-05-17Clinical Trial Update: Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 clinical trial evaluating bortezomib in Waldenström's macroglobulinemia has completed.
-
CLINICAL_TRIALS trial_result · 2013-02-12Clinical Trial Update: Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 trial update investigating rituximab with combination chemotherapy for newly diagnosed Waldenström's macroglobulinemia; the study is…
-
CLINICAL_TRIALS trial_result · 2013-02-01Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia [NA]
A clinical trial evaluated arsenic trioxide in patients with relapsed or refractory lymphoma and leukemia; the study status is terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-01-25Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder [Phase 1, Phase 2]
A Phase 1/2 trial evaluating Yttrium-90 ibritumomab tiuxetan in combination with rituximab for post-transplant lymphoproliferative disorder …
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 study evaluated oxaliplatin in patients with relapsed or refractory non-Hodgkin lymphoma across multiple subtypes and has complete…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma [Phase 2]
A Phase 2 trial investigating 506U78 in patients with recurrent or refractory non-Hodgkin's lymphoma and T-cell lymphomas was terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-14Clinical Trial Update: SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial of SB-715992 in patients with metastatic or unresectable solid tumors and various Hodgkin's and non-Hodgkin's lymphomas has be…
-
CLINICAL_TRIALS trial_result · 2013-01-08Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 1]
Phase 1 trial of Yttrium-90 ibritumomab tiuxetan (Zevalin) for Waldenström's macroglobulinemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-08Clinical Trial Update: Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 2]
A Phase 2 trial evaluating rituximab in combination with fludarabine for Waldenström's macroglobulinemia has completed.
-
CLINICAL_TRIALS trial_result · 2012-12-21Clinical Trial Update: Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia [Phase 2]
Phase II trial of Campath-1H (alemtuzumab) for Waldenström's Macroglobulinemia and Lymphoplasmacytic Lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2012-08-09Clinical Trial Update: Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood [Phase 2]
This entry summarizes a Phase 2 trial evaluating low-intensity conditioning followed by allogeneic stem cell transplantation for patients wi…
-
CLINICAL_TRIALS trial_result · 2012-04-30Clinical Trial Update: A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia [Phase 2]
Phase II trial evaluating ofatumumab in Waldenström macroglobulinemia; the study has completed and results were posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-02-16Clinical Trial Update: Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 trial evaluating perifosine in patients with relapsed/refractory Waldenström's macroglobulinemia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2012-02-10Clinical Trial Update: A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia [Phase 2]
A Phase 2 clinical trial evaluating belimumab for symptomatic Waldenström macroglobulinemia is reported, with no results provided and the tr…
-
CLINICAL_TRIALS trial_result · 2011-08-04Clinical Trial Update: Trial of AVN-944 in Patients With Advanced Hematologic Malignancies [Phase 1]
A Phase 1 trial evaluating AVN-944 in patients with advanced hematologic malignancies has completed, spanning acute and chronic leukemia, mu…
-
CLINICAL_TRIALS trial_result · 2011-07-15Clinical Trial Update: DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients [Phase 2]
Phase 2 trial update evaluating DT-PACE with tandem autologous transplant and maintenance therapy for Waldenström macroglobulinemia. The stu…
-
CLINICAL_TRIALS trial_result · 2011-06-27Clinical Trial Update: Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 clinical trial of bortezomib (Velcade) in Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2011-06-27Clinical Trial Update: Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia [NA]
A completed clinical trial update examining the correlation of Fc Gamma RIIIA (CD16) receptor response in patients with Waldenström macroglo…
-
CLINICAL_TRIALS trial_result · 2011-06-27Clinical Trial Update: Sildenafil Citrate in Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 trial evaluating sildenafil citrate for Waldenström macroglobulinemia has completed.
-
CLINICAL_TRIALS trial_result · 2011-06-22Clinical Trial Update: Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]
A Phase 1/2 trial of radiolabeled monoclonal antibody therapy with peripheral stem cell transplantation for lymphoma or Waldenström's macrog…
-
CLINICAL_TRIALS trial_result · 2011-02-21Clinical Trial Update: Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 study evaluating oblimersen sodium in combination with rituximab for recurrent B-cell non-Hodgkin lymphoma completed, with results…
-
CLINICAL_TRIALS trial_result · 2010-07-05Clinical Trial Update: Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia [Phase 2]
A completed Phase 2 clinical trial evaluated thalidomide as an anti-angiogenesis therapy in patients with Waldenström macroglobulinemia. The…
-
CLINICAL_TRIALS trial_result · 2009-06-25Clinical Trial Update: Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) [Phase 2]
This is an interventional Phase 2 trial evaluating a pentostatin, cyclophosphamide, and rituximab regimen for indolent B-cell non-Hodgkin ly…